G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Communications Officer Will Roberts will provide a corporate presentation on September 12, 2023, at 9:30 AM EDT during the H.C. Wainwright 25th Annual Global Investment Conference.

The webcast of the event will be accessible on the Events & Presentations page of http://www.g1therapeutics.com.

About G1 TherapeuticsG1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA® (trilaciclib). G1 has a deep clinical pipeline and is executing a development plan evaluating trilaciclib in a variety of solid tumors, including breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

G1 Therapeutics® and the G1 Therapeutics logo and COSELA® and the COSELA logo are trademarks of G1 Therapeutics, Inc

Contacts:Will RobertsCommunications OfficerVice President, Investor Relations & Corporate Communications919-907-1944 wroberts@g1therapeutics.com

G1 Therapeutics (NASDAQ:GTHX)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024 Plus de graphiques de la Bourse G1 Therapeutics
G1 Therapeutics (NASDAQ:GTHX)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024 Plus de graphiques de la Bourse G1 Therapeutics